Homrich & Berg lowered its position in Merck & Company, Inc. (NYSE:MRK) by 17.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 27,861 shares of the company’s stock after selling 5,784 shares during the quarter. Homrich & Berg’s holdings in Merck & were worth $1,786,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently modified their holdings of the stock. Boulegeris Investments Inc. boosted its holdings in Merck & by 77.8% in the second quarter. Boulegeris Investments Inc. now owns 9,252 shares of the company’s stock valued at $593,000 after acquiring an additional 4,048 shares during the last quarter. Evergreen Capital Management LLC acquired a new position in shares of Merck & during the second quarter worth about $265,000. Allen Investment Management LLC acquired a new position in shares of Merck & during the second quarter worth about $202,000. QCI Asset Management Inc. NY lifted its stake in shares of Merck & by 10.6% during the second quarter. QCI Asset Management Inc. NY now owns 2,494 shares of the company’s stock worth $160,000 after purchasing an additional 239 shares in the last quarter. Finally, Capital Analysts LLC lifted its stake in shares of Merck & by 0.5% during the second quarter. Capital Analysts LLC now owns 58,680 shares of the company’s stock worth $3,761,000 after purchasing an additional 270 shares in the last quarter. Hedge funds and other institutional investors own 72.98% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Merck & Company, Inc. (MRK) Shares Sold by Homrich & Berg” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright legislation. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/11/23/merck-company-inc-mrk-shares-sold-by-homrich-berg.html.

In other Merck & news, Director Thomas H. Glocer sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 8th. The stock was sold at an average price of $56.20, for a total value of $281,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.25% of the company’s stock.

A number of brokerages have commented on MRK. BMO Capital Markets restated a “buy” rating and set a $72.00 price objective on shares of Merck & in a research note on Friday, September 8th. BidaskClub cut Merck & from a “hold” rating to a “sell” rating in a research note on Wednesday, August 9th. Morgan Stanley cut Merck & from an “overweight” rating to an “equal weight” rating and set a $56.00 price objective on the stock. in a research note on Monday, October 30th. Credit Suisse Group restated an “outperform” rating and set a $74.00 price objective (down previously from $75.00) on shares of Merck & in a research note on Tuesday, September 5th. Finally, UBS AG reduced their price objective on Merck & from $72.00 to $67.00 and set a “buy” rating on the stock in a research note on Monday, October 30th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and ten have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $66.87.

Merck & Company, Inc. (MRK) opened at $54.37 on Thursday. Merck & Company, Inc. has a fifty-two week low of $53.63 and a fifty-two week high of $66.80. The stock has a market capitalization of $147,855.20, a P/E ratio of 13.95, a P/E/G ratio of 2.34 and a beta of 0.78. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.43 and a quick ratio of 1.16.

Merck & (NYSE:MRK) last issued its quarterly earnings data on Friday, October 27th. The company reported $1.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.03 by $0.08. Merck & had a return on equity of 27.08% and a net margin of 11.60%. The business had revenue of $10.33 billion during the quarter, compared to analyst estimates of $10.54 billion. During the same period in the prior year, the company posted $1.07 EPS. The business’s revenue for the quarter was down 2.0% compared to the same quarter last year. analysts anticipate that Merck & Company, Inc. will post 3.95 earnings per share for the current fiscal year.

Merck & Profile

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Institutional Ownership by Quarter for Merck & (NYSE:MRK)

Receive News & Stock Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related stocks with our FREE daily email newsletter.